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ABSTRACT
Background and Objectives: Left ventricular hypertrophy (LVH) is associated with poor 
cardiovascular outcomes. Heavy aortic calcification exacerbates arterial stiffness, which 
consequently heightens left ventricular (LV) afterload. We assessed the usefulness of aortic 
calcification for predicting adverse cardiovascular outcomes and to determine whether the 
relationship, if any, differed as a function of LVH.
Methods: The analytic sample was comprised of a total of 487 individuals 65 years of 
age or older. Thoracic aortic calcium score (TACS) was measured by coronary computed 
tomography, and patients were stratified according to the median (TACS, 446 mm3). LVH 
obtained from echocardiography was defined as LV mass index >115 g/m2 for men and >95 g/
m2 for women. Cox regression reporting hazard ratios (HRs) with 95% confidence intervals 
(CIs) was performed to predict the risk for the composite study endpoint, defined as cardiac 
death, admission for heart failure, obstructive coronary artery disease (CAD) requiring 
revascularization, or stroke.
Results: A total of 39 composite events (8.0%) occurred during a median follow-up of 65 
months (interquartile range [IQR], 17–89 months). For those with LVH, the concurrent 
presence of high TACS appeared to be an independent predictor (HR, 4.51; 95% CI, 1.71–
11.88; p=0.002) for the composite study endpoint. Other combined LVH and TACS subgroups 
were not associated with significant factors for predicting the composite study endpoint 
(p>0.050, all).
Conclusion: TACS provides robust predictive utility for a composite of cardiovascular events 
and cardiac death in persons with LVH. This finding was less pronounced in those with a 
relatively healthy myocardium, defined by the absence of LVH.
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INTRODUCTION
The presence of left ventricular hypertrophy (LVH) can heighten the risk of cardiovascular 
disease and mortality.1-3) LVH is frequently observed in hypertensive patients and has 
been considered an adaptive response to hemodynamic overload imposed by systemic 
hypertension.4) Although hypertrophic growth of cardiomyocytes is the chief mechanism for 
LVH, other pathologic mechanisms concurrently exist, including fibroblast proliferation and 
exaggerated accumulation of collagen fibers within the interstitium and perivascular regions, 
which provokes additional development of fibrosis and left ventricular (LV) dysfunction.5) 
Stiff cardiomyocytes and increased collagen deposition can trigger LV diastolic dysfunction 
— the major cardiac functional deficit in heart failure with preserved ejection fraction (EF).6)
Prior studies have documented that aortic calcium scoring is an independent prognosticator 
of cardiovascular events.7)8) Despite a well-known association between vascular calcification 
and clinical outcome, it remains unclear whether calcification has a direct impact on clinical 
outcomes or is merely a marker of atherosclerotic burden for each individual. We have 
previously reported that heavy aortic calcification and resultant arterial stiffening could be 
underlying causes of LVH and diastolic dysfunction in older-aged male patients that present 
with hypertension.9) Because myocardial afterload excess is currently thought to be a possible 
mechanism of diastolic heart failure, along with the progression of LVH,6) patients with 
LVH are more likely to experience symptoms of heart failure, as well as unfavorable clinical 
outcomes, in light of an increased afterload associated with a stiffened aorta due to heavy 
aortic calcification.
This study investigated the predictive utility of aortic calcification, a reflection of aortic 
stiffness, to determine if stiffness differed based on the presence of LVH. Specifically, we 
hypothesized that the impact of thoracic aortic calcium score (TACS) on clinical outcomes 
would be more profound in those with LVH, given that diseased myocardium is more likely to 
be vulnerable to afterload increase associated with aortic stiffness.
METHODS
Study population
We retrospectively reviewed a sample of 1,578 elderly individuals who were 65 years of age 
or above and who underwent concurrent coronary computed tomography (CT), exercise 
treadmill testing, and echocardiography to evaluate suspected coronary artery disease 
(CAD). The tests were performed within 90 days during 2003 through 2009 at Severance 
Cardiovascular Hospital, Seoul, Korea. Study individuals were excluded if they presented with 
obstructive CAD on coronary CT (luminal stenosis ≥50%), if their CT scan did not include 
the entire thoracic aorta from the aortic arch to diaphragm level, if they did not complete 
a minimum of 2 stages of the Bruce protocol exercise treadmill test, or if they reported the 
presence of atrial fibrillation, LVEF <50%, significant valvular dysfunction, or LVH related 
to either hypertrophic cardiomyopathy or infiltrative disease. Overall, 487 study individuals 
without obstructive CAD or LV systolic dysfunction were included in the analytic sample. 
The median number of days between coronary CT scans and exercise treadmill testing or 
echocardiography was 7 days (interquartile range [IQR], 2–14 days) and 8 days (IQR, 2–18 
days), respectively. The appropriate institutional review committee at Yonsei University, 
Severance Hospital in Seoul, Korea approved this study.
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Clinical examination
Clinical data were ascertained at baseline from routine medical history questionnaires, 
physical examination, and laboratory testing. In brief, body mass index (BMI) was calculated 
from height and weight measures. Diabetes mellitus was defined as receiving anti-diabetic 
treatment or a fasting plasma glucose of 126 mg/dL or more. Current cigarette smoking was 
defined as any cigarette smoking in the past month. Hypertension was defined as systolic 
blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg or use 
of antihypertensive agents. Dyslipidemia was defined as the use of cholesterol-lowering 
medication or a serum total cholesterol level of 200 mg/dL or more.
CT protocol and image acquisition
Patients were scanned using a 64-section CT scanner (Sensation 64; Siemens Healthineers, 
Forchheim, Germany). For calcium scanning, unenhanced CT was performed with 
prospective electrocardiography-triggered acquisitions in mid-diastole using 120–140 kV with 
150–220 mAs, depending on the patient's size; 240 milliseconds exposure time per rotation; 
330 milliseconds gantry rotation time; and 64×0.6 mm slice collimation. Calcium scans were 
reconstructed at 70% of the R-R interval using a slice thickness of 3 mm with an increment 
of 3 mm. Coronary artery calcium score (CACS) and TACS were measured on reconstructed 
images. Foci of the coronary artery, aortic valve, and thoracic aorta were identified and 
scored by an experienced technician who was blinded to the patient's medical records, using 
semi-automatic software (Vitrea 2.0; Vital Images, Minnetonka, MN, USA). Lesion-specific 
calcium scores were summed across all lesions identified within the left main, left anterior 
descending, left circumflex, and right coronary arteries to provide the CACS. In addition, the 
TACS included calcium that was scored in the ascending aorta, aortic arch, and descending 
aorta to the diaphragm level. An objective volume scoring approach included in the system 
software was determined, which provided a score in cubic millimeters (Figure 1).
Subsequently, coronary CT angiography was performed. Patients without a contraindication to 
beta-adrenergic blocking agents and with initial heart rate higher than 65 beats/min received a 
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Figure 1. TACS. 
TACS = thoracic aortic calcium score.
single oral dose of 40 mg propranolol hydrochloride 1 hour before coronary CT angiography. 
Two types of CT system configurations were employed: 1) a 64-slice CT scanner (Sensation 64; 
Siemens Healthineers) using retrospective electrocardiogram (ECG) gating with tube current 
modulation from 2003 through 2009 with the following parameters: rotation time, 330 ms; 
tube voltage, 100–120 KeV; tube current, 400–800 mA; and pitch factor, 0.2; and 2) a 64-row 
CT scanner (LightSpeed VCT XT; GE Healthcare, Milwaukee, WI, USA) using a prospectively 
ECG-gated axial technique from 2008 through 2009 with the following parameters: rotation 
time, 350 ms; tube voltage, 100–120 KeV; and tube current, 300–900 mA. A real-time bolus-
tracking technique was applied to trigger the scan initiation. Radiation doses for the calcium 
scan and total CT scan were 1.5±0.3 mSv and 10.7±2.8 mSv, respectively.
The intraobserver variability level in the TACS measurement was determined. Measurements 
were performed by one observer, based on analysis of 100 random images. The observer also 
performed repeated analysis in an interval of at least one month, while remaining blind to 
results from the first analysis.
Exercise testing
A symptom-limited exercise treadmill test was performed according to the Bruce protocol.10) 
Resting SBP and DBP were measured in the brachial artery in the seated position. During 
the exercise stress test, heart rhythm, SBP, and DBP were recorded at the end of each stage of 
exercise, at peak stress, and during recovery. ΔSBP was defined as the difference between SBP 
at rest and peak exercise. Pulse pressure (PP) was defined as the difference between SBP and 
DBP. ΔPP was defined as the difference in PP between rest and peak exercise. A 12-lead ECG 
was obtained every minute, and a 3-lead ECG for heart rhythm was monitored continuously. 
Indications for terminating the exercise treadmill test have been described previously.11)
Echocardiographic measurement
The dimensions of the left ventricle and EF were measured as recommended by the American 
Society of Echocardiography guidelines.12) LV mass was calculated using the formula as 
recommended, and LV mass index was defined as the LV mass indexed for body surface area. 
LVH was defined as an LV mass index >115 g/m2 for men and >95 g/m2 for women.12) Left atrial 
(LA) volume was calculated by use of standard criteria according to the American Society of 
Echocardiography recommendations, and the LA volume index was defined as the LA volume 
indexed for body surface area. Mitral inflow velocities were obtained by pulse wave Doppler in 
the apical four-chamber view. The mitral early diastolic velocity (E) was also measured. The 
peak early diastolic mitral annular velocity (e') was measured from the septal mitral annulus; 
we then calculated the E/e' ratio, which is a measure of the LV filling pressure.
Study endpoint
Study individuals were followed over a median of 65 months (IQR, 17–89 months) for a primary 
composite end-point of cardiac death, inpatient admissions for heart failure, obstructive 
CAD requiring revascularization or bypass surgery, and stroke. Clinical event occurrence was 
ascertained by review of hospital records and by telephone interview, if necessary.
Statistical methods
The distributions of relevant variables are reported as mean±standard deviation for continuous 
parametric variables, median with 25–75% range for non-parametric continuous variables, as 
necessary, or count with proportion for categorical measures. Both LVH and TACS groups were 
compared using Student's t-test for continuous variables and the χ2 statistics for categorical 
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parameters. Univariate Cox regression analysis reporting hazard ratio (HR) with 95% 
confidence interval (CI) was employed to determine independent predictors for the primary 
composite endpoint. Separate multivariate Cox regression models were generated according to 
the individually acquired coronary CT measures, as well as subsequent LVH and TACS strata. 
A Kaplan-Meier survival curve with log-rank test for equality was fashioned to display time-to-
events, which were stratified by LVH and TACS groups. The intraclass correlation coefficient 
(ICC) was calculated to evaluate intraobserver reproducibility. Good correlation was defined as 
an ICC >0.8. A p value <0.050 was considered statistically significant.
RESULTS
Overall, the median value of TACS was 446 mm3 (IQR, 132–1,223 mm3). Patients were 
divided into 4 groups according to the presence of LVH and TACS value. Low and high TACS 
values were defined as lower and higher TACS in comparison to median TACS, respectively. 
Demographic characteristics, TACS, CACS, and echocardiographic variables according to LVH 
and TACS are shown in Table 1. There were 171 patients with no LVH and low TACS, 73 patients 
with LVH and low TACS, 168 patients with no LVH with high TACS, and 75 patients with LVH 
and high TACS.
Table 2 reports resting and peak exercise SBP and PP values, as well as the Δ in both 
parameters, according to the presence of LVH and median value threshold of TACS. Resting 
SBP (128±17 mmHg vs. 124±16 mmHg, p=0.003) and PP (51±15 mmHg vs. 48±14 mmHg, 
p=0.022) were higher in those with LVH, although the ΔSBP (51±22 mmHg vs. 52±24 mmHg, 
p=0.631) and ΔPP (51±24 mmHg vs. 52±22 mmHg, p=0.720) were not very dissimilar between 
LVH groups. The high TACS group demonstrated a somewhat higher ΔSBP (54±23 mmHg 
vs. 50±23 mmHg, p=0.045) and ΔPP (54±24 mmHg vs. 49±22 mmHg, p=0.031), while resting 
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Table 1. Patient characteristics
Variables No LVH + low TACS (n=171) LVH + low TACS (n=73) No LVH + high TACS (n=168) LVH + high TACS (n=75) p value*
Age (years) 69±3 69±3 71±4 70±4 <0.001
Male 80 (46.5) 13 (17.8) 96 (57.1) 18 (24.3) <0.001
Hypertension 86 (50.0) 44 (60.2) 101 (60.1) 48 (64.8) 0.107
Diabetes mellitus 23 (13.3) 12 (16.4) 42 (25.0) 13 (17.6) 0.050
Dyslipidemia 85 (49.4) 29 (39.7) 88 (52.3) 36 (48.6) 0.331
BMI (kg/m2) 24.3±2.7 24.8±2.8 24.6±2.7 25.4±3.5 0.038
Laboratory test (g/dL)
Creatinine 0.94±0.24 0.87±0.15 0.99±0.20 0.91±0.24 <0.001
LDL-cholesterol 112.2±32.2 113.7±32.2 112.7±37.1 124.2±50.0 0.686
HDL-cholesterol 51.0±13.5 52.2±12.1 50.0±11.7 50.1±11.7 0.199
CT variables (mm3)
TACS 120 (37–261) 149 (47–261) 1,226 (790–2,291) 1,284 (747–2,336) <0.001
CACS 0 (0–27) 0 (0–20) 28 (0–161) 13 (0–95) 0.001
Echocardiography
LVEDD (mm) 46.5±3.7 49.6±3.7 46.3±4.1 49.5±4.3 <0.001
LVESD (mm) 30.2±3.7 32.3±3.7 30.2±3.5 32.2±4.2 <0.001
LVEF (%) 67.3±7.2 67.3±6.3 66.9±5.9 67.1±6.8 0.960
LVMI (g/m2) 80.7±14.5 111.4±13.6 83.3±13.0 117.6±16.0 <0.001
E/e' 11.0±3.3 11.3±2.9 11.5±4.0 13.1±3.8 0.001
Values are presented as mean±standard deviation or number of patients (%).
ANOVA = analysis of variance; BMI = body mass index; CACS = coronary artery calcium score; CT = computed tomography; E/e' = the ratio of early diastolic 
mitral inflow to mitral annular velocity; HDL = high density lipoprotein; LDL = low density lipoprotein; LVEDD = left ventricular end-diastolic dimension; LVEF = 
left ventricular ejection fraction; LVESD = left ventricular end-systolic dimension; LVH = left ventricular hypertrophy; LVMI = left ventricular mass index; TACS = 
thoracic aorta calcium score.
*p values were calculated by ANOVA for continuous variables and by χ2 test for categorical variables.
SBP (127±17 mmHg vs. 123±15 mmHg, p=0.006) and resting PP (51±15 mmHg vs. 47±13 
mmHg, p=0.003) also exhibited similarly elevated levels compared with the low TACS group.
Over a median follow-up period of 65 months (IQR, 17–89 months), there were 39 composite 
events (8.0%) including 2 cardiac deaths (0.4%), 12 inpatient admissions for heart failure 
(2.5%), 9 obstructive CADs requiring coronary intervention (1.8%), and 16 strokes (3.3%). 
In Table 3, univariate Cox regression analysis revealed that age (HR, 2.93; 95% CI, 1.33–6.42; 
p=0.007) and high TACS (HR, 2.34; 95% CI, 1.19–4.84; p=0.015) were significant predictors 
of the composite study endpoint. Further, in Table 4, multivariate Cox regression analysis 
found LVH to be an independent predictor (HR, 2.41; 95% CI, 1.19–4.90; p= 0.015) of the 
composite study endpoint, even after adjusting for age, gender, hypertension, diabetes 
mellitus, and BMI. High TACS was also an independent predictor (HR, 2.09; 95% CI, 
1.01–4.32; p=0.048) for study endpoint, even after adjusting for clinical variables. Notably, 
when patients were stratified according to the presence or absence of LVH and TACS, those 
with LVH and high TACS were at greater risk (HR, 4.51; 95% CI, 1.71–11.88; p=0.002) of 
experiencing the composite study endpoint, regardless of age, gender, hypertension, diabetes 
mellitus, and BMI (Table 4). The other strata of LVH and TACS did not have significant 
predictors for the composite study endpoint (p>0.050, all).
Figure 2 displays Kaplan-Meier survival curves for time-to-event stratified by LVH and TACS 
groups. In particular, among patients with LVH, the concurrent presence of a high TACS was 
associated with an unfavorable event-free survival (log-rank p=0.039), whereas for individuals 
without LVH, time to events did not differ for those with either a high or low TACS (log-rank 
p=0.109). When the patients were divided based on the presence of LVH, LVH was not found 
to be associated with significant prognostic markers in patients with low TACS (long-rank 
p=0.783), while LVH demonstrated borderline significance for predicting poor prognosis for 
those with high TACS (log-rank p=0.099).
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Table 2. Blood and PP changes based on LVH and TACSs
Variables LVH TACS
No Yes p value Low High p value
Resting SBP 124±16 128±17 0.003 123±15 127±17 0.006
Peak SBP 175±25 180±27 0.020 173±25 180±27 0.001
ΔSBP 51±22 52±24 0.631 50±23 54±23 0.045
Resting PP 48±14 51±15 0.022 47±13 51±15 0.003
Peak PP 99±25 101±28 0.283 96±24 103±27 0.001
ΔPP 52±22 51±24 0.720 49±22 54±24 0.031
LVH = left ventricular hypertrophy; PP = pulse pressure; SBP = systolic blood pressure; TACS = thoracic aorta calcium score; ΔPP = difference in pulse pressure 
between rest and peak exercise; ΔSBP = difference between systolic blood pressure at rest and peak exercise.
Table 3. Univariate HRs for predicting composite study endpoints
Variables HR 95% CI p value
Age (per 10-year increments) 2.93 1.33–6.42 0.007
Male 1.28 0.68–2.42 0.445
Hypertension 1.03 0.54–1.96 0.935
Diabetes 1.13 0.50–2.56 0.775
Dyslipidemia 1.35 0.71–2.56 0.360
BMI (per kg/m2) 1.02 0.91–1.13 0.783
High TACS 2.34 1.19–4.84 0.015
CACS ≥400 2.52 0.84–7.12 0.297
LVH 1.81 0.95–3.45 0.071
BMI = body mass index; CACS = coronary artery calcium score; CI = confidence interval; HR = hazard ratio; LVH = left ventricular hypertrophy; TACS = thoracic 
aorta calcium score.
The ICC for intraobserver reproducibility was 0.999 (95% CI, 0.998–0.999) for TACS in non-
contrast CT scan, suggesting excellent correlation.
DISCUSSION
The principal finding of this study was that TACS is a robust predictor for a composite of 
cardiovascular events and cardiac death in older-aged individuals with LVH, whereas the 
prognostic role of TACS independent of LVH was less pronounced; the latter might indicate a 
relatively healthy myocardium without strucutural impairment. To our knowledge, this is the 
first study to document the differntial prognostic utility of TACS based on the vulnerability of 
individual myocardial properties.
LVH is frequently found in hypertensive patients and results from complex interactions among 
several hemodymic and non-hemodynamic components.5) LVH usually occurs in response 
to hemodynamic overload in some physiological and pathological conditions. Hypertrophic 
growth of cardiomyocytes is a key mechanism of LVH, by which the heart reduces the LV wall 
and stress is caused by systemic pressure overload.13) In addition to increased afterload with 
high blood pressure, other elements such as ethnicity, gender, environmental influences, 
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Table 4. Multivariate HRs for predicting composite study endpoint
Variables HR 95% CI p value
Model 1
Age (per 10-year increments) 2.58 1.14–5.55 0.023
Male 1.15 0.60–2.21 0.681
Hypertension 1.16 0.60–2.24 0.660
Diabetes mellitus 1.29 0.56–2.99 0.550
BMI (kg/m2) 1.02 0.91–1.13 0.755
High TACS 2.09 1.01–4.32 0.048
Model 2
Age (per 10-year increments) 3.31 1.47–7.43 0.004
Male 1.64 0.81–3.33 0.172
Hypertension 1.17 0.60–2.26 0.651
Diabetes mellitus 1.17 0.41–2.68 0.720
BMI (kg/m2) 1.01 0.91–1.13 0.795
LVH 2.41 1.19–4.90 0.015
Model 3
Age (per 10-year increments) 2.77 1.22–6.28 0.015
Male 1.53 0.75–3.12 0.239
Hypertension 1.90 0.99–3.64 0.610
Diabetes mellitus 1.27 0.95–3.49 0.576
BMI (kg/m2) 1.01 0.91–1.12 0.843
LVH 2.36 1.16–4.78 0.015
High TACS 2.03 0.98–4.21 0.056
Model 4
Age (per 10-year increments) 2.78 1.23–6.31 0.014
Male 1.52 0.82–2.89 0.243
Hypertension 1.18 0.61–2.29 0.620
Diabetes mellitus 1.25 0.54–2.89 0.601
BMI (kg/m2) 1.01 0.91–1.12 0.950
LVH + TACS group
No LVH + low TACS - - -
LVH + low TACS 1.69 0.48–5.97 0.418
No LVH + high TACS 1.67 0.66–42.30  0.280
LVH + high TACS 4.51 1.71–11.88 0.002
BMI = body mass index; CI = confidence interval; HR = hazard ratio; LVH = left ventricular hypertrophy; TACS = thoracic aorta calcium score.
obesity, as well as neurohumoral and genetic considerations could affect the LV mass.14-16) 
Secretion of vasoactive peptides can increase during LVH and can significantly impact LVH 
caused by high blood pressure. Although antihypertensive treatments can reduce blood 
pressure levels in hypertensive patients, it has been reported that this approach is not always 
useful for delaying or preventing LVH.17) LVH leads to an increased myocardial mass/volume 
ratio, and the degree of hypertrophy is associated with chamber stiffness. Fibrillar collagen, as 
well as cardiomyocyte hypertrophy, accumulates in the extracellular space and the reactive and 
progressive interstitial, and perivascular fibrosis accounts for abnormal myocardial stiffness in 
LVH and, ultimately, LV systolic and diastolic dysfunction.18)
Aortic stiffness is associated with diastolic dysfunction in patients with early stage 
hypertension or diabetes mellitus, which suggests a common pathophysiological link 
between aortic stiffness and LV diastolic function, irrespective of LVH.19)20) We previously 
reported on the association between heavy aortic calcification and arterial stiffening in 
elderly male patients with hypertension and subsequently propose that the role of aortic 
calcification might reflect a simple imaging surrogate of aortic stiffness.9) In this study, we 
found that patients with LVH and a high TACS experienced the poorest clinical outcomes 
compared with the other subgroups, including those without LVH and those with LVH and 
low TACS (though TACS values did not differ between LVH groups). Therefore, based on 
these results, the impact of aortic calcification on adverse clinical outcomes might be more 
prominent in patients with LVH, despite similarities in the total amount of aortic calcium 
deposits in those with and without LVH.
This finding could be caused by diseased myocardium such as LVH, which is more easily 
influenced by afterload increase associated with aortic stiffness. A similar exaggerated 
systolic load interaction has been documented in patients that present with heart failure and 
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Figure 2. Kaplan-Meier survival curves displaying time-to-event rates stratified according to LVH and TACS. 
LVH = left ventricular hypertrophy; TACS = thoracic aorta calcium score.
preserved systolic function. Moreover, aortic stiffness can potentially exacerbate LV systolic 
load interaction with diastolic function, and this ventricular-systolic and arterial stiffening 
might further exacerbate blood pressure lability and diastolic dysfunction under stress, which 
is often present in patients with heart failure and preserved systolic function.21) Undoubtedly, 
further studies are needed to evaluate the impact of high TACS on clinical outcomes, as well as 
LVH progression and diastolic function, in various diseases that involve the myocardium, such 
as heart failure and cardiomyopathies. In addition, further investigation is required to identify 
an approach for combining LVH and TACS to efficiently predict cardiovascular outcomes.
In contrast to the current study, Kim et al.22) demonstrated that, in the presence of CACS=0, 
measurement of TACS is unlikely to provide sufficient additional prognostic information 
to further improve risk assessment. The differential prognostic impact would be caused 
by the difference in aortic calcium burdens between the study populations. We previously 
demonstrated that the conflicting data on the prognostic role of aorta calcification 
resulted from the amounts of calcium deposited in the aortic wall, and that heavy aortic 
calcification would be required to cause remarkable changes in arterial stiffness with vascular 
calcification.23) In this study, we found that those with low TACS showed relatively low 
CACS (median of 0) value. Therefore, the presence of CACS=0 might suggest that thoracic 
aortic calcium burden is also too low to modify arterial stiffness and clinical outcomes. 
Consequently, low CACS, which reflects relatively low TACS in the population, would not 
alter vascular stiffness or clinical outcomes.
In this study, resting SBP and PP were higher in the LVH group compared with the no LVH 
group, although the ΔSBP and ΔPP did not differ between those with or without LVH. Of 
note, when subjects were divided into 2 categories on the background of low or high TACS, 
both resting and peak exercise hemodynamic variables demonstrated clear differences 
between the low and high TACS groups. Based on this result, it is possible that a potential 
mechanism mediates unfavorable clinical outcomes in patients with high TACS and could 
be associated with the dynamic rise of SBP and the widening of PP during exercise; however, 
additional studies are necessary to support this hypothesis.
The current findings were based on a retrospective analysis, which limits this study from 
inferring a causal relationship between TACS or CACS and the composite endpoint. Despite 
this, we carefully reviewed all medical records and CT images in an effort to avoid possible 
biases. Arterial stiffness was not measured, and follow-up echocardiography data were not 
obtained. Hence, the current study was unable to confirm whether arterial stiffness and/or 
high aortic calcification might have aggravated the progression of LVH. Further studies with 
concurrent measures of arterial stiffness, aortic calcification, and serial echocardiography 
are warranted to support this conclusion. Although we excluded patients with myocardial 
disease, such as hypertrophic cardiomyopathy or infiltrative cardiomyopathy, it can be 
difficult to differentiate early stages of diffuse type hypertrophic cardiomyopathy from 
LVH in patients with a hypertensive heart condition. Therefore, the cause of LVH in some 
of the patients remains unclear, although other risk factors such as ethnicity, gender, 
environmental influences, obesity, and neurohumoral and genetic factors might affect 
LV mass. Traditional ardiovascular risk factors for cardiovascular outcomes, such as 
hypertension and diabetes mellitus, were not risk factors for outcomes in the current study. 
We excluded patients with obstructive CAD who were at high risk for future cardiovascular 
events related to ischemic heart disease, and the exclusion of these high-risk populations 
of CAD might have resulted in the lack of association with traditional CAD risk factors. 
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Therefore, it is difficult to distinguish ascending aortic root calcification from aortic valve 
calcification. For better diagnostic accuracy, we rechecked the use of reformatted sagittal 
and coronal planes in cases where the differentiation between aorta and valve calcification 
was difficult, based on axial images. Although different prognostic roles between intimal 
and medial calcification are important issues related to aortic calcification, we could not 
differentiate intimal calcification from medial calcification. Unfortunately, because there is 
not currently a method for differentiating intimal calcification from medial calcification in 
intact aorta (without dissection) by CT imaging or by other non-invasive imaging modalities, 
further studies are required to find a novel method for localizing vascular calcification. 
Inclusion of the entire chest wall is necessary to assess TACS from coronary calcium scan. 
Although this might raise questions about the full field of view, this approach is advantageous 
for early detection of lung cancer and other lung diseases.24) Furthermore, the radiation dose 
in our study was too low for a calcium scan, even with a full field of view (mean value of 1.5 
mSv). We cannot discount the possibility that the number of events in the current study 
might have been underreported, as we relied primarily on gathering events data from hospital 
reports. Nevertheless, such underestimation of events would likely have been mitigated by a 
comparable underestimation across all groups.
In this study, the prognostic impact of TACS was different between patients with LVH 
and those without LVH. TACS provided a robust diagnostic approach for a composite of 
cardiovascular events in older-aged individuals with LVH. The findings were less pronounced 
in those with relatively healthy myocardium, as demonstrated by the absence of LVH. The 
impact of TACS, which might translate into afterload increase, should be accounted for when 
attempting to offset the progression of disease, especially in patients with established LVH.
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